Full Press Release Details
Dr. Han Myint Appointed as NextCure's
Chief Medical Officer
BELTSVILLE, Md. - January 14, 2021 - NextCure,
Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class
immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP
as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure's product pipeline,
including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed
to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at
both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.
"We are very excited that Han has joined the NextCure
team. We believe the depth of his expertise in oncology product development will prove instrumental in the advancement of our product
pipeline," said Michael Richman, NextCure's president and chief executive officer. "Han's strong industry
track record is highlighted by his involvement in the development of multiple U.S. Food and Drug approved products."
"I'm thrilled to join NextCure at this important
time in the company's growth," said Dr. Myint. "I believe that the company, through its powerful discovery platform,
has created a pipeline of novel immunomedicines, including NC318 and NC410, with the potential to have a significant impact in
Dr. Myint has over 20 years of experience in both academia
and the biopharma industry. Before joining NextCure, he was chief medical officer at NexImmune, a clinical-stage
biotechnology company developing unique approaches to T cell immunotherapies. Prior to NexImmune, he was Vice President of
Global Medical Affairs and the Myeloid Diseases Lead at Celgene. His work in myeloid diseases at Celgene contributed to a
number of FDA approvals, successful launches of those products and high-impact publications. Prior to joining the biopharma
industry, Dr. Myint practiced medicine specializing in hematological oncology and conducted clinical and laboratory research
at multiple prestigious academic institutions in the UK and USA including Rush University Medical Center in Chicago and
University of Colorado, Denver. Dr. Myint, Professor of Medicine, built a FACT-accredited and Center of Excellence-Designated
Stem Cell Transplant Program at the University of Colorado, Denver. He has in-depth scientific knowledge, a wealth of
clinical experience and expertise in hematological malignancies and stem cell transplantation. Dr. Myint graduated from the
Institute of Medicine in Yangon with a MBBS degree and subsequently emigrated to the UK to do his postgraduate training in
Internal Medicine, followed by his training in Hematology. Accordingly, he was awarded as a fellow from the Royal Colleges of
Physicians and Pathologists from the UK and also from the American College of Physicians.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed
to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through
our proprietary FIND-IO platform, we study various immune cells to discover and understand targets and structural components
of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments
to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with
cancer types not adequately addressed by available therapies. www.nextcure.com
Forward-Looking Statements
press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other
information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure's
expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "may,"
"will," "potential," "expects," "believes," "intends," "hope,"
"towards," "forward," "later" and similar expressions. Examples of forward-looking statements
in this press release include, among others, statements about the progress and evaluation and expected timing of results of NextCure's
ongoing clinical trial of NC318, expectations regarding the potential benefits, activity, effectiveness and safety of NC318, the
evaluation of biomarkers, future clinical trials of NC318, the hiring and onboarding of a new chief medical officer and NextCure's
plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements
involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking
statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure's business,
including NextCure's clinical trials, third parties on which NextCure relies and NextCure's operations; positive results
in preclinical studies or early-stage clinical trials may not be predictive of the results of later clinical trials; NextCure's
limited operating history and no products approved for commercial sale; NextCure's history of significant losses; NextCure's
need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and dependence
on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results
are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's
most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. Forward-looking
statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements,
even if expectations change.
Timothy Mayer, Ph.D.
Chief Operating Officer